The most effective post-first CR1 treatment for patients with AML, allogenic hematopoietic SCT (allo-HSCT) or autologous hematopoietic SCT (HSCT), remains to be conclusively determined. This study aimed to compare the effectiveness of treatment with allo-HSCT or auto-HSCT in patients with AML after CR1. We retrospectively reviewed medical records of 127 patients with AML who received allo-(n ¼ 52) or auto-HSCT (n ¼ 75) after achieving CR1 at a single medical center. The disease-free and overall survival rates and complications were analyzed. During a median follow-up of 1215 days, all patients (100%) in allo-HSCT group and 94.7% of patients in the auto-HSCT group had successful outcomes. The disease-free survival rates were 65.3% and 50.6% for allo-and auto-HSCT groups, respectively (P ¼ 0.158), while the overall survival rates were 65.3% and 54.9%, respectively (P ¼ 0.486). The recurrence rate was higher with auto-HSCT, whereas the GVHD only happened with allo-HSCT. In conclusion, auto-HSCT was as effective as allo-HSCT for the treatment of patients with AML after CR1. This is encouraging given that allo-HSCT is not always feasible in China because of a lack of matching donors.
INTRODUCTION
Patients with AML who achieve CR1 typically receive subsequent consolidation chemotherapy or hematopoietic SCT (HSCT), either allogeneic (allo-HSCT) or autologous (auto-HSCT), depending on donor availability. The National Comprehensive Cancer Network (http://www.nccn.org) recommends consolidation chemotherapy for patients with good risk AML and allo-HSCT for patients with poor risk AML. In support of these recommendations, findings from a recent meta-analysis suggest that allo-HSCT increases disease-free and overall survival compared with nonallogeneic HSCT therapies (consolidated chemotherapy, auto-HSCT) in patients with intermediate to poor risk AML. 1 There is also evidence to suggest that auto-HSCT may improve various measures of survival compared with consolidated chemotherapy. [2] [3] [4] [5] [6] Nevertheless, the most effective post-CR1 treatment for patients with AML remains to be conclusively determined. 7, 8 In the present study, we reviewed the medical records of patients with AML who received allo-or auto-HSCT, after achieving CR1 at a single medical center, to determine the most effective treatment strategy. The main aim of our study was to compare disease-free and overall survival rates between patients with AML who received allo-or auto-HSCT. Secondary aims included identifying risk factors for recurrence and mortality, and comparing disease-free and overall survival rates between patients who received BMT and those receiving peripheral blood HSCT.
MATERIALS AND METHODS Patients
We reviewed the medical records of patients with AML who achieved CR1 and received subsequent auto-or allo-HSCT from April 1985 to March 2008 in Chinese PLA General Hospital. All patients were continuously treated at the same institution without exclusion. This study was approved by the Institutional Review Board of Chinese PLA General Hospital.
Conditioning regimen
All patients received a conditioning regimen before transplantation. Patients received one of the following conditioning regimens: modified BuCy (Bu, 1 mg/kg/6 h for 3 days; Cy, 50 mg/kg/day for 2 days); 9 etoposide/ TBI/Cy (E-TBICy: E, 150 mg/m 2 for 1 day; TBI, total 800-1000 cGy over one or two doses; Cy, 50 mg/kg/day for 2 days); (BuACy: Bu, 1 mg/kg/6 h for 2 days; A, 3.0 g/day for 1 days; Cy, 50 mg/kg/day for 2 days). Patients also received 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea (250 mg/m 2 ). For patients receiving unrelated HSCT, antithymocyte globulin was given at 3 mg/kg/day for 4 days from day 4 to day 1.
Bone marrow transplantation
Under continuous epidural anesthesia, 1000-1500 mL of heparin anticoagulated BM was collected from the iliac crest and mixed in RPMI 1640 medium. The median (range) number of mononuclear cells (MNCs) for transplantation was 2.62(0.37-4.9) Â 10 8 /kg. For patients with matching blood types in allo-BMT, BM was directly transfused. For patients with major blood type incompatibilities, RBCs were removed from BM before transplantation, whereas for patients with minor blood type incompatibilities, plasma was removed before transplantation. During transplantation, protamine sulfate was administered according to the amount of heparin used. For auto-BMT, the cells were kept at 4 1C (with heparin as an anticoagulant) and then transfused (within 72 h) back into patients after pretreatment.
Allogeneic peripheral blood hematopoietic SCT All donors were human leukocyte Ag 10 of the 10 matches with recipients. Donors received 5 days of treatment with s.c. recombinant human G-CSF (10 mg/kg/day) before stem cells were collected. MNCs were isolated using a Cobe Spectra separator (Lakewood, CO, USA). The extracorporeal volume was two times the whole blood volume (8 000-12 000 mL). The final volume of the collected stem cell suspension was 100-200 mL. The number of CD34 þ cells transfused was 2.3-9.8 Â 10 6 /kg, whereas the number of colony-forming unit-granulocytes/monocytes transfused was 1.8-6.7 Â 10 5 /kg. The collected stem cell suspension was directly transfused to the recipient. For patients with major or mixed blood type incompatibilities, dexamethasone (5 mg) was administered before transplantation. After transplantation, patients were hydrated, monitored for renal function, and treated with sodium bicarbonate and diuretics until the urine became clear.
Autologous peripheral blood HSCT
Once WBC counts began to increase to 1.0 Â 10 9 /L after combined chemotherapy, G-CSF (5-10 mg/kg/day) was administered subcutaneously.
Hematopoietic stem cells were collected when the WBC count was 45.0 Â 10 9 /L. Peripheral blood MNCs were isolated using a Baxter CS-3000 Plus or a COBE spectra, cryopreserved at À 80 1C, and subsequently transfused into the patient within 6 months. Prevention of GVHD in allo-HSCT CsA (2-3 mg/kg/day) was intravenously infused for 2-3 weeks after transplantation and was given orally once patients had started eating. Blood CsA concentrations were maintained between 200 and 400 mg/L. MTX (15 mg/m 2 ) was intravenously infused on day þ 1, 10 mg/m 2 on days þ 3, þ 6 and þ 11. Oral mycophenolate mofetil was given from the day before transplantation for 28 days. For patients with unrelated hematopoietic SCT, CD25 Ab was given one to two times on day 0 or on days 0 and þ 4. All blood products (except for donor hematopoietic stem cells) were irradiated at 2500 cGy before transplantation.
Prevention and treatment of hepatic veno-occlusive disease
For all patients, compound Danshen (20 mL/day) and low MW dextran (500 mL/day) were intravenously infused from the beginning of conditioning until the platelet count was 30 Â 10 9 /L or coagulation deficiency was apparent.
End points measures
The primary end points of interest were disease-free survival and overall survival. Disease-free survival was the time from CR to relapse or death of any cause.
Other end points of interest included engraftment success rate, recurrence and mortality. Engraftment success was indicated by granulocyte counts 40.5 Â 10 9 /L for 3 consecutive days or platelet counts 420 Â 10 9 /L in the absence of platelet transfusion. Transplantation failure was indicated by a granulocyte count o0.5 Â 10 9 /L, or the absence of donor cells as shown by variable copy numbers of tandem repeats analysis at day þ 28. Recurrence was indicated by a greater than 5% proportion of primitive cells in the BM, development of disease, or extramedullary relapse following CR.
Statistical analysis
Continuous data are expressed as median (interquartile range) and were compared between groups by Mann-Whitney U test. Categorical data are expressed as count (percentage) and were compared between groups by Fisher's exact test. Disease-free and overall survival curves were constructed using the Kaplan-Meier method and were compared between groups (allogeneic vs autologous; BMT vs peripheral blood HSCT) by log-rank test. Cox proportional hazard models were used to identify independent risk factors for recurrence and mortality. Significant factors identified by univariable Cox proportional hazard models were selected for inclusion in the final multivariable Cox proportional hazard model using the forward conditional method. All analyses were evaluated at the 0.05 level of statistical significance. Statistical analyses were performed using SPSS 15.0 statistical software (SPSS Inc., Chicago, IL, USA).
RESULTS

Demographic and clinical characteristics
A total of 127 patients with AML were included in the study; 76 males and 51 females, with a median age of 31 years. Among these patients, 75 (59.1%) were treated with auto-HSCT; 38 received auto-BMT, 35 received peripheral blood HSCT, and 2 patients received both auto-BMT and auto-peripheral blood HSCT. The remaining 52 (40.9%) patients were treated with allo-HSCT; 12 patients received allo-BMT; 39 patients received allo-peripheral blood HSCT; and 1 patient received both allo-BMT and alloperipheral blood HSCT from the same donor. The distribution of FAB types included: 9 (7.1%) AML-M1; 40 (31.5%) AML-M2; 12 (9.4%) AML-M3; 31 (24.4%) AML-M4; 26 (20.5%) AML-M5; and 6 (4.7%) AML-M6. Of the remaining 3 patients, one had basophilic leukemia, one had obvious MDS history and then transformed to AML-M2, and one was unclassified AML.
Patients in the allo-HSCT group were significantly older than those in the auto-HSCT group (Table 1 , P ¼ 0.018). All 12 patients with AML-M3 were in the auto-HSCT group. There were significantly more patients with enlarged lymph nodes or hepatosplenomegaly in the allo-HSCT group compared with auto-HSCT group (28.8 vs 12.0%, P ¼ 0.022). The time between diagnosis and HSCT was significantly longer in the auto-HSCT group compared with the allo-HSCT group (295.0 days vs 203.5 days, Po0.001). There were significantly more chemotherapy induction courses to obtain CR and consolidation chemotherapy cycles from CR to HSCT in the auto-HSCT group compared with the allo-HSCT group (median number of induction courses to CR ¼ 2.0 vs 1.0, P ¼ 0.013; median number of cycles from CR to HSCT ¼ 5.0 vs 3.0, Po0.001). Patients in the auto-HSCT group received significantly more consolidation therapy cycles than patients in the allo-HSCT group (4.0 vs 3.0, Po0.001). In terms of conditioning regimens, 84% patients in the auto-HSCT group received the TBI/Cy regimen, whereas only 69.2% of patients in the allo-HSCT group received this regimen; 12.0% patients in auto-HSCT group received Bu/Cy and 26.9% in allo-HSCT group (P ¼ 0.041).
HSCT outcome and complications The median follow-up was 1215 days (range: 14-8286 days). HSCT was successful in all patients (100%) treated with allo-HSCT and 94.7% of patients treated with auto-HSCT ( Table 2 , P ¼ 0.144). Aphthous ulcer, erythra and upper respiratory tract infection occurred more frequently in the allo-HSCT group compared with the auto-HSCT group (aphthous ulcer: 59.6 vs 14.7%, Po0.001; erythra: 19.2 vs 2.7%, P ¼ 0.003; upper respiratory tract infection: 9.6% vs 1.3%, P ¼ 0.042). The rates of acute and chronic GVHD were 42.3 and 13.5%, respectively, in the allo-HSCT group, whereas there were no instances of GVHD in the auto-HSCT group ( Table 2 ). The disease-free survival rates in auto-HSCT group and allo-HSCT group were 50.6 and 65.3%, respectively (Figure 1a , P ¼ 0.158), whereas the overall survival rates in auto-HSCT group and allo-HSCT group were 54.9 and 65.3%, respectively (Figure 1b , P ¼ 0.486). Predictors of mortality Univariable analysis revealed that gender, the symptom of fever, the proportion of BM primitive cells, radiotherapy dose and the type of conditioning regimen were significant predictors of mortality (Table 4) . Subsequent multivariable analyses revealed that the symptom of fever, the proportion of BM primitive cells and the type of conditioning regimen were the independent significant predictors of mortality. When controlling for factors of proportion BM primitive cells and conditioning regimens, patients with the symptom of fever were found to have a significantly lower risk of mortality (HR ¼ 0.417, P ¼ 0.003); the risk of mortality decreased with every percentage increase in the proportion of BM primitive cells (HR ¼ 0.984, P ¼ 0.018). Patients treated with the Bu/Cy conditioning regimen had a significantly lower risk of mortality than patients who were treated with the other conditioning regimens (TBI/Cy vs Bu/Cy: HR ¼ 4.952, P ¼ 0.008; other regimens vs Bu/Cy: HR ¼ 8.388, P ¼ 0.009).
BMT vs peripheral blood HSCT A total of 50 patients received BMT, whereas 74 patients received peripheral blood HSCT. The other three patients received both BMT and peripheral blood HSCT. Figure 2 shows the disease-free and overall survival rates for patients who received BMT and those who received peripheral blood HSCT, stratified by the source of HSCTs (autologous or allogeneic). For both the auto-and allo-HSCT groups, disease-free survival rates were lower (but not significantly so) for patients who received BMT compared with patients who received peripheral blood HSCTs (the 3-year survival rate for auto-HSCT: BMC ¼ 43.0% vs peripheral blood HSCT ¼ 58.9%; the 3-year survival rate for allo-HSCT: BMC ¼ 48.6% vs peripheral blood HSCT ¼ 69.2%). Similarly, for both the autoand allo-HSCT groups, overall survival rates were lower (but not significantly so) for patients who received BMT compared with Note: three patients who had both BMT and peripheral blood HSCT were excluded from these analyses.
patients who received peripheral blood HSCTs (auto-HSCT: BMC ¼ 52.1% vs peripheral blood HSCT ¼ 58.9%; allo-HSCT: BMC ¼ 48.6% vs peripheral blood HSCT ¼ 69.2%).
DISCUSSION
In this retrospective study, we examined outcomes of Chinese patients with AML received allo-or auto-HSCT following CR1. We found that there were no significant differences in disease-free or overall survival rates between patients who received allogenic HSCT and those who received auto-HSCT, although the rate of survival was numerically higher in the allo-HSCT group. In elderly patients with non-M3 acute myelogenous leukemia in first CR, Kurosawa et al. 10 reported that allo-HCT may improve outcomes (compared with chemotherapy) in patients with AML in CR1. Our finding that there were no significant differences in disease-free or overall survival between patients who received allo-HSCT and auto-HSCT are consistent with those from a smallscale study (N ¼ 99) reporting 3-year survival rates for patients who received high-dose cytarabine followed by either allo-HSCT, auto-HSCT or a second dose of cytarabine. 8 In contrast, the findings from several larger-scale studies (N ¼ 734-831) with longer reported survival rates suggest that allo-HSCT/ BMT is associated with better survival outcomes than auto-HSCT/ BMT. [11] [12] [13] Hsieh et al.
14 also reported that allo-HSCT was associated with the best disease-free survival and overall survival in comparison with auto-HSC or chemotherapy in patients with cytogenetically normal AML. If donors with all HLA matching are available, we suggest using allo-HSCT. In cases where HLA matching donors are not available, auto-HSCT is a good choice. A large clinical trial also reported that early allo-HSCT treatment led to better overall results than auto-HSCT, especially for younger patients or those with bad/very bad risk cytogenetics. 12 The lack of any significant between-group differences in our study may reflect the relatively short duration of follow-up and/or the fact that all 12 patients with M3 FAB subtype, which is associated with the best prognosis and not suggested for HSCT in CR1, were in the auto-HSCT group. Another potential explanation is that Chinese patients respond differently to these forms of treatment than Caucasian patients.
Of note, multivariable Cox proportional hazard model analysis revealed that conditioning treatment with BuCy was associated with both decreased rates of disease recurrence and mortality. This finding is unsurprising given that the other conditioning regimens, involving radiotherapy and/or chemotherapy, are associated with more pronounced toxicities and side effects. 15, 16 Interestingly, we also found that the symptom of fever and the proportion of BM primitive cells were significant predictors of disease-free and overall survival. These are surprising findings that are difficult to explain. As already noted, all patients were in CR before receiving HSCT. It is possible that a high proportion of tumor blast cells would require a more complete treatment, thereby leading to better survival outcomes. The patients with fever may have had more pronounced myelosuppression than patients who did not have fever. This possibility may have provided a more favorable environment for not only pretreatment, but also the homing and engraftment of transplanted cells, therefore resulting in better outcomes. Further studies are needed to explore these unexpected findings.
Our study has a number of limitations that warrant acknowledgment, including the retrospective design and the relatively small number of patients from a single institution. Our study groups also lacked homogeneity before treatment for some variables, which, as already mentioned, may have affected outcomes. Largerscale studies are needed to further elucidate the optimal post-CR1 treatment approach for Chinese patients with AML.
In conclusion, our findings suggest that auto-HSCT is equally as effective as allo-HSCT in terms of subsequent disease-free and overall survival for patients with AML, post-CR1. If a donor with all HLA matching is available, allo-HSCT is still the first choice. This finding is encouraging given that allo-HSCT is not always feasible in China because of a lack of all HLA matching donors.
